ARCHIVES

Legacy CEO Cheryl Healton says foundation could serve as funder for research on “potentially reduced-exposure products.”

This article is from The Cancer Letter archive.

Vol. 30 No. 41 | October 29, 2004

Download PDF Visit The Full Archive

Related Articles

Senate Committee Approves $1.74 Billion for NCI, Seeks Activation of Dietary Intervention Trial

October 19, 1990

Cancer Incidence, Mortality Rates Trend Downward, NCI, ACS Say In “Report Card”

March 13, 1998

AACR, Kellogg’s Co. Sponsor Award

January 5, 1996

Clinical Trials: Phase I Trial of Karenitecin Begins, BioNumerik Says

March 5, 1999

ASCO TO NCI: Review Auditing Procedures, Re-Establish Trust

May 27, 1994

After the Plenary: Don Berry: In NeoALTTO & ALTTO Trials, Neoadjuvant Response Predicts Adjuvant

June 11, 2014